Enfermedad de Fabry: la importancia de la terapia de reemplazo enzimático (TRE), tratar rápida y eficazmente
Resumen
La enfermedad de Fabry en un trastorno lisosomal por ausencia o deficiencia de la enzima Alfa galactosidasa A que genera un acúmulo patológico de glicoesfingolípidos principalmente en células endoteliales, musculares lisas de vasos sanguíneos y podocitos entre otras. La terapia de reemplazo enzimático es la única chance de tratamiento específico a la fecha. El creciente conocimiento de los mecanismos fisiopatológicos ha llevado a cambiar el manejo de la enfermedad y por sobretodo el momento de inicio del tratamiento. Actualmente el inicio en edades más tempranas parece ser una forma de evitar y en algunos casos revertir algunos de los signos y síntomas de la enfermedad de Fabry.Citas
Desnick RJ, Ioannou YA, Eng CM. α-galactosidase A deficiency: Fabry disease. In : Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic bases of inherited disease. 8rd ed. New York : MacGraw-Hill, 2001; p 3733-74.
Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H , et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79(1):31-40.
Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab. 2008;93(2):112-28.
Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G, et al. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr. 2006;95(1):86-92.
Gal A, Hughes DA, Winchester B. Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group. J Inherit Metab Dis. 2011;34(2):509-14.
Chamoles NA, Blanco M, Gaggioli D. Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta. 2001; 308(1-2):195-6.
Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285(21):2743-9.
Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med. 2001;345(1):9-16.
Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003;138(4):338-46.
Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006;8(9):539-48.
Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE. Bouwman MG et al. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis. 2013;8:47.
Weidemann F, Niemann M, Störk S, Breunig F, Beer M, Sommer C, et al. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med. 2013;274(4):331-41.
Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol. 2007;18(5):1547-57.
Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M , et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2007;146(2):77-86.
Grupo Mexicano de Especialidades en Enfermedad de Fabry. [Diagnosis, assessment, and treatment guideline for Fabry disease]. Rev Med Inst Mex Seguro Soc. 2009;47(5):505-14.
Lidove O, Bekri S, Goizet C, Khau Van Kien A, Aractingi S, Knebelmann B, et al. [Fabry disease: proposed guidelines from a French expert group for its diagnosis, treatment and follow-up]. Presse Med. 2007;36(7-8):1084-97.
Grupo Argentino de Diagnóstico y Tratamiento de la Enfermedad de Fabry (GADYTEF). Guía práctica para el estudio, diagnóstico y tratamiento de la enfermedad de Fabry. Rev Nefrol Dial Traspl. 2007;27(4):159-70.
García de Lorenzo A; en nombre del Grupo de Enfermedad de FABRY-GETER. [Consensus for the study and treatment of Fabry disease. GETER Foundation]. Med Clin (Barc). 2011;137(4):178-83.
Thurberg BL, Politei JM. Histologic abnormalities of placental tissues in Fabry disease: a case report and review of the literature. Hum Pathol. 2012;43(4):610-4.
Najafian B, Svarstad E, Bostad L, Gubler MC, Tøndel C, Whitley C, et al. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney Int. 2011;79(6):663-70.
Tøndel C, Bostad L, Hirth A, Svarstad E. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis. 2008;51(5):767-76.
Burlina AP, Sims KB, Politei JM, Bennett GJ, Baron R, Sommer C, et al. Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol. 2011;11:61.
Reina MA, López A, Villanueva MC, de Andrés JA, León GI. [Morphology of peripheral nerves, their sheaths, and their vascularization]. Rev Esp Anestesiol Reanim. 2000;47(10):464-75.
